哌拉西林/他唑巴坦治疗成人复杂性尿路感染的真实世界研究  

Real-world study on piperacillin-tazobactam in the treatment of complicated urinary tract infection in adults

作　　者：杨义 李明 李娜 文志鹏 赵兵 YANG Yi;LI Ming;LI Na;WEN Zhipeng;ZHAO Bing(Dept.of Pharmacy,the Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China;Institution of Clinical Drug Trial,the Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China)

机构地区：[1]贵州医科大学附属医院药学部,贵阳550004 [2]贵州医科大学附属医院药物临床试验机构,贵阳550004

出　　处：《中国药房》2024年第14期1753-1758,共6页China Pharmacy

基　　金：贵州省药品评价中心项目。

摘　　要：目的 探讨哌拉西林/他唑巴坦治疗成人复杂性尿路感染(cUTI)的有效性和安全性。方法 回顾性分析2021年1月1日至2023年12月31日我院成人c UTI患者资料352例,所有患者均使用哌拉西林/他唑巴坦。观察患者的病原菌检出情况,治疗后的临床有效率、微生物清除率、不良反应发生情况及治疗费用。结果 352例患者中,有54例患者有病原菌培养结果,以产超广谱β-内酰胺酶大肠埃希菌为主(48.1%)。所有患者的临床有效率为94.3%,微生物清除率为81.5%,不良反应发生率为1.4%。临床有效患者中的男性比例、泌尿外科治疗患者比例均显著高于临床无效患者,而移植科治疗患者比例、合并移植肾患者比例均显著低于临床无效患者(P<0.05)。根据病原菌对哌拉西林/他唑巴坦的敏感性分为目标治疗组和经验性治疗组的分析结果显示,两组患者的临床有效率比较,差异无统计学意义(P=0.902 5)。结论 哌拉西林/他唑巴坦治疗成人cUTI的疗效显著,安全性较好。OBJECTIVE To investigate the efficacy and safety of piperacillin-tazobactam in the treatment of complicated urinary tract infection(cUTI) in adults.METHODS Retrospective analysis was performed on the data of 352 cUTI adult patients in our hospital from January 1,2021 to December 31,2023.All patients received piperacillin-tazobactam.The detection of pathogens in patients,the clinical efficacy and microbial clearance rate after treatment,the occurrence of adverse drug reactions and treatment cost were observed in all patients.RESULTS Of the 352 patients,pathogen culture results of 54 patients were detected,mainly Escherichia coli producing extended-spectrum beta-lactamases.The clinical effective rate was 94.3%,the microbial clearance rate was 81.5%,and the incidence of adverse reactions was 1.4%.The percentage of male effective patients in urinary surgery department was significantly higher than invalid patients,while the proportion of transplant treatment and the proportion of patients with concomitant kidney transplantation were significantly lower than invalid patients(P<0.05).There was no significant difference in clinical effective rate between the two groups after those patients were divided into target treatment group and empirical treatment group according to the sensitivity of pathogen to piperacillin-tazobactam(P=0.902 5).CONCLUSIONS Piperacillin-tazobactam is effective and safe in the treatment of cUTI.

关 键 词：哌拉西林/他唑巴坦 复杂性尿路感染 病原菌 有效性 安全性 

分 类 号：R978.1[医药卫生—药品]